NASDAQ:AXDX - Accelerate Diagnostics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$21.52 +2.05 (+10.53 %)
(As of 02/21/2019 08:54 AM ET)
Previous Close$19.47
Today's Range$18.7360 - $22.35
52-Week Range$10.23 - $27.65
Volume793,221 shs
Average Volume413,293 shs
Market Capitalization$1.17 billion
P/E Ratio-13.28
Dividend YieldN/A
Beta3.11
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.

Receive AXDX News and Ratings via Email

Sign-up to receive the latest news and ratings for AXDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AXDX
CUSIPN/A
Phone520-365-3100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.67 million
Book Value$2.14 per share

Profitability

Net Income$-64,020,000.00
Net Margins-1,564.01%

Miscellaneous

EmployeesN/A
Market Cap$1.17 billion
OptionableOptionable

Accelerate Diagnostics (NASDAQ:AXDX) Frequently Asked Questions

What is Accelerate Diagnostics' stock symbol?

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics Inc (NASDAQ:AXDX) announced its quarterly earnings results on Tuesday, February, 19th. The medical research company reported ($0.41) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.41). The medical research company had revenue of $1.80 million for the quarter, compared to the consensus estimate of $1.83 million. Accelerate Diagnostics had a negative net margin of 1,564.01% and a negative return on equity of 95.07%. View Accelerate Diagnostics' Earnings History.

When is Accelerate Diagnostics' next earnings date?

Accelerate Diagnostics is scheduled to release their next quarterly earnings announcement on Wednesday, May 8th 2019. View Earnings Estimates for Accelerate Diagnostics.

What guidance has Accelerate Diagnostics issued on next quarter's earnings?

Accelerate Diagnostics updated its FY 2018 earnings guidance on Monday, January, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $5.7-5.7 million, compared to the consensus revenue estimate of $6.63 million.Accelerate Diagnostics also updated its Q4 2018 guidance to EPS.

What price target have analysts set for AXDX?

3 Wall Street analysts have issued 12 month price targets for Accelerate Diagnostics' stock. Their forecasts range from $16.00 to $25.00. On average, they expect Accelerate Diagnostics' share price to reach $21.00 in the next twelve months. This suggests that the stock has a possible downside of 2.4%. View Analyst Price Targets for Accelerate Diagnostics.

What is the consensus analysts' recommendation for Accelerate Diagnostics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Accelerate Diagnostics.

Has Accelerate Diagnostics been receiving favorable news coverage?

Media headlines about AXDX stock have been trending positive on Thursday, according to InfoTrie. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Accelerate Diagnostics earned a daily sentiment score of 2.5 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next several days.

Who are some of Accelerate Diagnostics' key competitors?

Who are Accelerate Diagnostics' key executives?

Accelerate Diagnostics' management team includes the folowing people:
  • Mr. Lawrence Mehren, Pres, CEO, Director and Interim Head of Europe, Middle East & Africa (Age 53)
  • Mr. Steve Reichling, Chief Financial Officer (Age 41)
  • Mr. Ron Price, Sr. VP & Head of Commercial Operations - Americas (Age 55)
  • Mr. Kurt Reinhardt, Head of Operations
  • Dr. Romney M. Humphries, Chief Scientific Officer

Who are Accelerate Diagnostics' major shareholders?

Accelerate Diagnostics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Amundi Pioneer Asset Management Inc. (1.83%), Stifel Financial Corp (1.03%), Artal Group S.A. (0.92%), Nuveen Asset Management LLC (0.82%), Northern Trust Corp (0.65%) and Geode Capital Management LLC (0.57%). Company insiders that own Accelerate Diagnostics stock include Jack W Schuler, John Patience, Lawrence Mehren, Steven Reichling and Thomas D Brown. View Institutional Ownership Trends for Accelerate Diagnostics.

Which major investors are selling Accelerate Diagnostics stock?

AXDX stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., Nuveen Asset Management LLC, D. E. Shaw & Co. Inc., Natixis Advisors L.P., Obermeyer Wood Investment Counsel Lllp, Albion Financial Group UT, CIBC Private Wealth Group LLC and Northern Trust Corp. View Insider Buying and Selling for Accelerate Diagnostics.

Which major investors are buying Accelerate Diagnostics stock?

AXDX stock was acquired by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Raging Capital Management LLC, Stifel Financial Corp, Intrinsic Edge Capital Management LLC, RMB Capital Management LLC, First Trust Advisors LP, Thompson Investment Management Inc. and Rhumbline Advisers. Company insiders that have bought Accelerate Diagnostics stock in the last two years include Jack W Schuler, John Patience, Steven Reichling and Thomas D Brown. View Insider Buying and Selling for Accelerate Diagnostics.

How do I buy shares of Accelerate Diagnostics?

Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Accelerate Diagnostics' stock price today?

One share of AXDX stock can currently be purchased for approximately $21.52.

How big of a company is Accelerate Diagnostics?

Accelerate Diagnostics has a market capitalization of $1.17 billion and generates $5.67 million in revenue each year. The medical research company earns $-64,020,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis.

What is Accelerate Diagnostics' official website?

The official website for Accelerate Diagnostics is http://www.acceleratediagnostics.com.

How can I contact Accelerate Diagnostics?

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at 520-365-3100 or via email at [email protected]


MarketBeat Community Rating for Accelerate Diagnostics (NASDAQ AXDX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  192 (Vote Outperform)
Underperform Votes:  205 (Vote Underperform)
Total Votes:  397
MarketBeat's community ratings are surveys of what our community members think about Accelerate Diagnostics and other stocks. Vote "Outperform" if you believe AXDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel